PET显像对三阴性乳腺癌的影响:更新的循证视角
本系统综述检索PubMed、Scopus和Web of Science至2024年2月,纳入28项研究共2870例三阴性乳腺癌患者,评估PET在TNBC管理中的作用。基线[18F]FDG摄取与PDL-1、雄激素受体和Ki67等分子标志物相关,基线PET可使患者从IIB期升级至IV期;新辅助化疗中系列PET的SUVmax变化可预测病理完全缓解。作者认为[18F]FDG PET对初始分期和新辅助化疗疗效评估有用,需进一步前瞻性研究。
要点
- 基线[18F]FDG PET可使TNBC患者从IIB期升级至IV期,影响治疗决策和生存结局。
- 新辅助化疗中系列PET的SUVmax变化可预测pCR,不同截断值对应不同缓解率。
- 基线[18F]FDG摄取与PDL-1、雄激素受体和Ki67等分子标志物存在显著关联。
核心结论
- 在TNBC患者中,[18F]FDG PET对局限性和转移性疾病的初始分期均至关重要,也适用于评估新辅助化疗的治疗反应。
- PET将代谢活性与分子标志物关联并预测治疗结局的能力凸显其在TNBC管理中的潜力。
- 需要进一步前瞻性研究来完善这些临床适应证并确立其确切作用。
研究设计与样本
- 系统综述,检索PubMed、Scopus和Web of Science数据库至2024年2月。
- 由五名研究人员组成团队进行数据提取和分析,并使用特定评估表评估所选研究的质量。
- 共纳入28项研究,涉及2870例TNBC患者。
主要发现
- 两项研究使用PSMA配体显像剂,大多数研究使用基于[18F]FDG的PET。
- 基线[18F]FDG摄取与PDL-1、雄激素受体和Ki67等分子生物标志物之间存在显著关联。
- 基线[18F]FDG PET导致患者从IIB期升级至IV期,影响治疗决策和生存结局。
- 在新辅助化疗中,系列PET测量的[18F]FDG摄取变化(以SUVmax表示)可预测pCR,不同截断值与不同缓解率相关。
- 代谢肿瘤体积(MTV)和PET肺指数等半定量参数对转移性疾病具有预后价值。
关键数值与推荐
- 基线[18F]FDG PET使TNBC患者从IIB期升级至IV期。
- 系列PET的SUVmax变化预测pCR,不同截断值对应不同缓解率。
- MTV和PET肺指数等半定量参数对转移性疾病具有预后价值。
临床怎么用
- 作者认为[18F]FDG PET对TNBC患者局限性和转移性疾病的初始分期至关重要。
- 作者认为[18F]FDG PET可用于评估新辅助化疗的治疗反应。
- 作者认为PET将代谢活性与分子标志物关联并预测治疗结局的能力凸显其在TNBC管理中的潜力。
局限性
- 需要进一步前瞻性研究来完善这些临床适应证并确立其确切作用。
以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。
原文
INTRODUCTION: Triple-negative breast cancer (TNBC) is a subtype of breast cancer characterized by the absence of estrogen, progesterone, and HER2 receptors. It predominantly affects younger women and is associated with a poor prognosis. This systematic review aims to evaluate the current role of positron emission tomography (PET) in the management of TNBC patients and to identify future research directions. METHODS: We systematically searched the PubMed, Scopus, and Web of Science databases up to February 2024. A team of five researchers conducted data extraction and analysis. The quality of the selected studies was assessed using a specific evaluation form. RESULTS: Twenty-eight studies involving 2870 TNBC patients were included in the review. Key clinical applications of PET in TNBC included predicting pathological complete response (pCR) in patients undergoing neoadjuvant chemotherapy (NAC), assessing the prognostic value of baseline PET, and initial disease staging. Two studies utilized PSMA-ligand agents, while the majority used [18F]FDG-based PET. Significant associations were found between baseline [18F]FDG uptake and molecular biomarkers such as PDL-1, androgen receptor, and Ki67. Baseline [18F]FDG PET led to the upstaging of patients from stage IIB to stage IV, influencing treatment decisions and survival outcomes. In the NAC setting, serial PET scans measuring changes in [18F]FDG uptake, indicated by maximum standardized uptake value (SUVmax), predicted pCR with varying cut-off values correlated with different response rates. Semiquantitative parameters such as metabolic tumor volume (MTV) and PET lung index were prognostic for metastatic disease. CONCLUSIONS: In TNBC patients, [18F]FDG PET is essential for initial disease staging in both localized and metastatic settings. It is also useful for assessing treatment response to NAC. The ability of PET to correlate metabolic activity with molecular markers and predict treatment outcomes highlights its potential in TNBC management. Further prospective studies are needed to refine these clinical indications and establish its definitive role.
引用
- Filippi L, Urso L, Ferrari C, et al. The impact of PET imaging on triple negative breast cancer: an updated evidence-based perspective. Eur J Nucl Med Mol Imaging. 2024. PMID: 39110196. doi:10.1007/s00259-024-06866-9
供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。